

Cover Story
By Matthew Bin Han Ong
NCI is using a hub-and-spoke structure to engineer an ambitious data federation for pediatric cancers—which, if done right, is anticipated to become the gold standard for a new generation of comprehensive cancer databases.
In Brief


Funding Opportunities
Clinical Roundup
Drugs & Targets


NCI Trials


NCI Trials for December 2020
The National Cancer Institute approved the following clinical research studies last month.


Trending Stories
- Brawley: ACS prostate cancer screening guideline should say no to “mass screening”
- NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations - Kay “Taddy” Dickersin, NBCC co-founder, dies at 74
- CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality - In the 90s, Barry Kramer persuaded NCI to get out of the business of screening guidelines
At the time, USPSTF was better equipped to do the job. Is it still?















